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Effect size in depressionMeta-analyses indicate that antidepressants are superior to placebos in statistical terms, but the clinical relevance
of the differences has not been established. Previous suggestions of clinically relevant effect sizes have not been
supported by empirical evidence. In the current paper we apply an empirical method that consists of comparing
scores obtained on the Hamilton rating scale for depression (HAM-D) and scores from the Clinical Global Impres-
sions-Improvement (CGI-I) scale. This method reveals that a HAM-D difference of 3 points is undetectable by
clinicians using the CGI-I scale. A difference of 7 points on the HAM-D, or an effect size of 0.875, is required to cor-
respond to a rating of ‘minimal improvement’ on the CGI-I. By these criteria differences between antidepressants
and placebo in randomised controlled trials, including trials conducted with people diagnosed with very severe
depression, are not detectable by clinicians and fall far short of levels consistent with clinically observable min-
imal levels of improvement. Clinical signiﬁcance should be considered alongside statistical signiﬁcance when
making decisions about the approval and use of medications like antidepressants.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Decisions about the approval and use of medications should not
be based on statistical signiﬁcance alone. Estimation of the clinical rele-
vance of drug-placebodifferences is also necessary, to balance the utility
of a drug's effects against its side effects and health risks. Antidepres-
sants have been compared with placebo in numerous randomised
controlled trials. The methodological ﬂaws of these studies have been
widely discussed and include selective publication and outcome
reporting, bias introduced by placebo washout procedures, infringe-
ment of the double bind, and inﬂation of drug-placebo differences
through categorisation of data [1–3]. Despite these problems, there
remains a consensus that antidepressants have worthwhile effects in
people with more severe depression, at least. The difference between
antidepressants and placebo in the treatment of major depression is
small, however. Mean differences between antidepressants and placebo
reported inmeta-analyses of the Food and Drug Administration data set
have ranged from 1.80 to 2.56 points on the widely used Hamilton
rating scale for depression (HAM-D) [4], with effect sizes (d) ranging
from 0.31 to 0.32 [5–8]. In some studies [6,9], effects varied as a function
of baseline severity ranging from d = 0.11 for patients in the mild to
moderate range (HAM-D ≤ 18) to 0.47 for patients with very severe
depression (HAM-D ≥ 23) [9], although another study as failed to ﬁnd
a severity effect [8].irvkirsch@gmail.com (I. Kirsch).
. This is an open access article under1. Deﬁning clinical relevance
Until recently there have been no empirically validated criteria for
establishing the clinical signiﬁcance of change scores on scalesmeasuring
psychiatric symptoms. In the 2004 National Institute of Health and Clini-
cal Excellence (NICE) guidelines on treating depression, it was suggested
that differences of three points on the HAM-D and standardized mean
differences of 0.50 might be clinically signiﬁcant [10], but no evidence
was cited to support these proposed cut-offs, and they were criticised as
arbitrary [11]. The speciﬁcation of criteria for clinical relevance was
removed from the later edition of the Guidance published in 2009, but
effects continued to be classiﬁed according to their ‘clinical importance,’
apparently using the same criteria proposed in the 2004 Guidance [12].
For example, based on a standardized mean difference of 0.34, the 2009
updated NICE guidance concluded that the difference between SSRIs
and placebos is “unlikely to be of clinical importance” (p. 317).
Subsequently, an empirical method of establishing the clinical rele-
vance of change scores has been reported in a number of studies
[13–16]. The method links scores on various scales used in psychiatric
outcome trials to scores on the commonly used Clinical Global Impres-
sions-Improvement (CGI-I) scale, a scale which rates improvement on
a scale of 1 (very much improved) through 4 (no change) to 7 (very
much worse) [17]. The CGI-I is said to be ‘intuitively understood by
clinicians’ ([16], p 243) and has good inter-rater reliability, between
0.65 and 0.92 [18]. It has been judged to be a useful measure in clinical
trials [19] and shown to have concurrent validity with other measures,
including CGI severity ratings [20–22]. Spearman correlations rangingthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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[17]. Thus, this method allows one to align the degree of change on a
symptom scale to clinician perception of improvement, and provides a
means of establishing an empirically derived criterion for clinical signif-
icance. The method has been applied to scales measuring symptoms of
schizophrenia [14,15], and more recently to depression scales, speciﬁ-
cally the HAM-D. We suggest that a CGI-I rating of 3, which indicates
that the patient has “minimally improved” provides the most liberal
criterion possible, as the next step on the scale is “no change.”
2. The clinical relevance of antidepressant effects
Leucht et al. [16] used the raw data on the antidepressant
mirtazapine gathered from 43 trials in more than 7000 people diag-
nosed with ‘major depressive disorder’. The data were derived from
placebo-controlled, comparative and open label trials that had been
sponsored by the drug company, Organon. The linking analysis of abso-
lute change in Hamilton scores to CGI-improvement scores at four time
points is presented in Fig. 1.
Leucht and colleagues described these data as follows: ‘The results
were consistent for all assessment points examined. A CGI-I score of 4
(“no change”) corresponds with a slight reduction on the HAM-D-17
of up to 3 points’ ([16], p 245–246). In other words, clinicians could
not detect a difference of 3 points on the Hamilton when asked to rate
a patient's overall improvement. Examination of the ﬁgure reveals
that a CGI-I score of 3 (‘minimally improved’) corresponded to changes
in Hamilton score of around 7 points after two to four weeks of treat-
ment. To attain a CGI score of 2 (‘much improved’), required a change
in Hamilton score of 14 points at the four week assessment.
To date, thismethod has been used to establish the clinical relevance
of pre–post treatment differences. We propose that it can also serve as
an empirically validated method of evaluating the clinical signiﬁcance
of drug-placebo differences, since these are also frequently calibrated
in terms of differences on the Hamilton scale. Applying this to
placebo-controlled antidepressant trials, Leucht et al.'s [16] data reveal
that the 3-point difference in HAM-D scores proposed by NICE is overly
lenient. It results in classifying a difference that cannot be detected by
clinicians as clinically important. These data suggest that a difference
of 7-points on the HAM-Dmight be a more reasonable cut-off, as it cor-
responds to a clinician rating of minimal improvement.
Leucht and colleagues also reported that the correspondence of
HAM-D change scores to clinical ratings varied somewhat as a function
of baseline severity. For less severely depressed patients, a clinicianFig. 1. *Reprinted from J Affect Disord, 148 (2,3), Leucht S, Fennema H, Engel R, Kaspers-
JanssenM, Lepping P, SzegediA.What does theHAMDmean?243–8, (2013),with permis-
sion from Elsevier.rating of minimal improvement corresponded to a 6-point HAM-D dif-
ference, whereas for very severely depressed patients, it corresponded
to an 8-point change.
3. Interpreting effect sizes (d)
One problem with the cut-offs proposed by NICE (2004) is that a 3
point difference in HAM-D change scores does not correspond well to
the effect size of d= 0.50 that was proposed to indicate clinical signiﬁ-
cance. The pooled SD of change scores in the Kirsch et al. meta-analysis
(N = 5133) was 8.0 (7.9 for the investigational drug and 8.2 for place-
bo) [6]. However, that meta-analysis did not include the medication
assessed in the Leucht et al. analysis (i.e., mirtazapine). More important,
it did not include comparator studieswithout placebo arms,whichwere
included in the Leucht et al. paper. Thus, it seemed important to assess
the reliability of our SD estimate using other data.
A meta-analysis of 5 placebo-controlled mirtazapine trials yielded
change score SDs of 7.7 formirtazapine and 8.3 for placebo [23]. Reported
in the same paper, a meta-analysis of 5 trials comparing mirtazapine to
amitriptyline yielded SDs of 7.9 and 7.8, respectively. A later comparator
trial [24] reported SDs of 7.5 formirtazapine and 7.7 for paroxetine. These
data reveal substantial consistency in the variance of HAM-D change
scores across different trial designs, antidepressants, and placebos.
Using an SD of 8.0, the effect size (d) corresponding to a difference
score of 7-points (i.e., a clinician rating of minimally improved) is
0.875. For very severely depressed patients, the effect size correspond-
ing to a minimal difference would be 1.00, and for less severely
depressed patients it would be a 0.75. These are the effect sizes that
are required to indicate a ‘minimal’ difference as rated by clinicians.
They are more than twice the magnitude of the effect sizes derived
from meta-analyses, including those examining separately people
with the most severe levels of depression [6,7,9].
Conventionally, an effect size of 0.50 is considered ‘medium’ and
0.80 is considered ‘large.’ However, Cohen proposed these cut-offs
with “invitations not to employ them if possible. The values chosen
had no more reliable a basis than my own intuition” [25] (p 534).
The data considered here suggest that with respect to changes on
the HAM-D, effect sizes as large as 1.00 may be required to indicate
‘minimal’ differences as rated by clinicians.
4. Discussion
Over the last few decades antidepressants have become some of the
most widely used and proﬁtable drugs in history. Rates of prescriptions
have risen throughout the developed world [26], leading to debates
about the inappropriate medicalization of misery [27]. Themore funda-
mental question, however, is whether antidepressants achieve worth-
while effects in depression in general. Guidelines have attempted to
consider the issue of clinical relevance of antidepressant effects, but
have not constructed empirically validated criteria.
The commonly used method of estimating the ‘response’ to drug
treatment in clinical trials of antidepressants (arbitrarily set at a 50% re-
duction in symptoms), involves the categorisation of continuous data
from symptom scales, and therefore does not provide an independent
arbiter of clinical signiﬁcance. Moreover, this method can exaggerate
small differences between interventions such as antidepressants and
placebo [28], and statisticians note that it can distort data and should
be avoided [29,30]. Response rates in double-blind antidepressant trials
are typically about 50% in the drug groups and 35% in the placebo
groups (e.g., [31,32]). This 15% difference is often defended as clinically
signiﬁcant on the grounds that 15% of depressed people who get better
on antidepressants would not have gotten better on placebo. However,
a 50% reduction in symptoms is close to the mean and median of drug
improvement rates in placebo-controlled antidepressant trials [31–33]
and thus near the apex of the distribution curve. Thus, with an SD of 8
in change scores, a 15% difference in response rates is about (an odds
62 J. Moncrieff, I. Kirsch / Contemporary Clinical Trials 43 (2015) 60–62ratio of 1.86, a relative risk of 0.77, and an NNT of 7) is exactly what one
would expect from a mean 3-point difference in HAM-D scores [28].
Lack of response does not mean that the patient has not improved; it
means that the improvement has been less, by as little as one point,
than the arbitrary criterion chosen for deﬁning a therapeutic response.
The small differences detected between antidepressants and placebo
may represent drug-induced mental alterations (such as sedation or
emotional blunting) or ampliﬁed placebo effects rather than speciﬁc
‘antidepressant’ effects [34]. At a minimum, therefore, it is important to
ascertain whether differences correlate with clinically detectable and
meaningful levels of improvement. The CGI has been criticised for not
reﬂecting the patient's perspective [35], and other data such as function-
ing and quality of life measures are also required to fully assess the value
of antidepressant treatment. Cuijpers et al. [36] have proposed a different
method of establishing a ‘minimal important difference’ (MID) based on
‘utility’ measures derived from quality of life scales. However, the study
fromwhich theMIDwas estimated did not include samples of depressed
individuals, and the values obtained were found to be unstable. As a
result, the authors were only able to provide a “very rough estimate
of the cutoff for clinical relevance” (p. 376). Use of a patient-rated
version of the CGI might allow for a more reliable and valid complement
to the clinician-rated data used here to assess the clinical relevance of
HAM-D scores. In its absence, CGI improvement scores provide the ﬁrst
empirically validated method for establishing the clinical relevance of
antidepressant effects. Based on the Leucht et al. data [16], empirically
derived criteria for minimal clinically relevant drug-placebo differences
would be, a 7-point difference in HAM-D change scores (8 points for
very severely depressed patients), and a drug-placebo effect size (d) of
0.875 (1.00 for very severely depressed patients). Currently, drug effects
associated with antidepressants fall far short of these criteria.
This leaves the problem of how to treat depressed patients, given
data indicating little if any difference in clinically relevant effects
between one treatment and another [33]. Patients and healthcare
funders need to be aware that all treatments, including placebo, pro-
duce at least a minimal average response to treatment on symptom
scales (i.e., improvement of at least 7 points on the HAM-D), while
none outperforms a pill placebo to a meaningful degree. We suggest
that decisions about treatment should involve the balancing of criteria
including patient preference, safety, and cost. Given the choice, most
depressed patients prefer psychotherapy over medication [37], and
with respect to safety, antidepressant medication would be the last
choice between empirically assessed treatment alternatives [38].
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